Evogene Ltd

NASDAQ:EVGNUnited States

Nov 21, 2024

Show headlines and story abstract

• -- Earnings Flash (EVGN) EVOGENE Reports Q3 Revenue $1.8M, vs. Street Est of $2.9M, from 7:35AM ET on Thursday Nov 21, 2024 by MT Newswires

  7:35AM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: EVGN
  07:35 AM EST, 11/21/2024 (MT Newswires) -- ...

• -- Earnings Flash (EVGN) EVOGENE Reports Q3 Loss $-1.31 Per Share, from 7:32AM ET on Thursday Nov 21, 2024 by MT Newswires

  7:32AM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: EVGN
  07:32 AM EST, 11/21/2024 (MT Newswires) -- ...

• Evogene Reports Third Quarter 2024 Financial Results, from 7:30AM ET on Thursday Nov 21, 2024 by PR Newswire

  7:30AM ET on Thursday Nov 21, 2024 by PR Newswire
  Companies Mentioned: EVGN

  Conference call and webcast: today, November 21, 2024, 9:00 am ET

  Financial Highlights:

  -- In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023.

• Evogene Reports Third Quarter 2024 Financial Results, from 7:30AM ET on Thursday Nov 21, 2024 by Dow Jones

  7:30AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: EVGN
  ============ ============ ============ ========== ============== Attributable to: Equity holders of the Company (16,912) (17,278) (7,630) (3,984) (23,879) Non-controlling interests (1,137) (1,339) (589) 126 (2,075) ------------ ------------ ------------ ---------- -------------- $ (18,049) $ (18,617) $ (8,219) $ (3,858) $ (25,954) Basic and diluted loss per share, attributable to equity holders of the Company (*) $ (3.17) $ (3.91) $ (1.31) $ (0.81) $ (5.20) ============ ============ ============ ========== ============== Weighted average number of shares used in computing basic and diluted loss per share (*) 5,327,078 4,423,661 5,807,128 4,913,052 4,589,386 ============ ============ ============ ========== ============== (*) Shares and per shares amounts have been retroactively adjusted to reflect the reverse stock split CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS ---------------------------------------------------------------------------------- U.S. dollars in thousands Year ended Nine months ended Three months ended December September 30, September 30, 31, ------------------------- ----------------------- ------------ 2024 2023 2024 2023 2023 ------------ ----------- ----------- ---------- ------------ Unaudited -------------------------------------------------- ------------ Cash flows from operating activities: --------------- Loss $ (18,049) $ (18,617) $ (8,219) $ (3,858) $ (25,954) Adjustments to reconcile loss to net cash used in operating activities: Adjustments to the profit or loss items: Depreciation 1,182 1,223 382 416 1,641 Amortization of intangible assets 729 726 245 245 971 Share-based compensation 1,478 1,764 479 545 1,877 Remeasurement of pre-funded warrants and warrants (1,940) - (1,940) - - Revaluation of convertible SAFE (48) 177 (72) (43) 254 Net financing expenses (income) 943 (206) 1,165 (212) (666) Loss (gain) from sale of property, plant and equipment 524 (26) - - (26) Excess of initial fair value of pre-funded warrants over transaction proceeds 2,684 - 2,684 - - Amortization of deferred expenses related to issuance of warrants 137 - 137 - - Share of loss of an associate 26 - 6 - - Taxes on income (tax benefit) 2 (29) 1 (5) (33) 5,717 3,629 3,087 946 4,018 ------------ ----------- ----------- ---------- ------------ Changes in asset and liability items: Increase in trade receivables (1,233) (997) (1,214) (1,167) (9) Decrease (increase) in other receivables 601 (420) 1,326 (504) (1,445) Decrease (increase) in inventories (1,380) 453 (662) 136 490 Decrease in deferred taxes - - - - 94 Increase (decrease) in trade payables (534) 179 228 153 742 Increase (decrease) in employees and payroll accruals (248) 72 (44) (100) 550 Increase (decrease) in other payables 139 (467) 353 (305) (534) Increase (decrease) in deferred revenues and other advances (96) 190 (12) 263 (288) (2,751) (990) (25) (1,524) (400) ------------ ----------- ----------- ---------- ------------ Cash received (paid) during the period for: Interest received 646 433 244 150 905 Interest paid (56) (92) (15) (26) (115) Tax paid - (15) - (5) (31) ------------ ----------- ----------- ---------- ------------ Net cash used in operating activities $ (14,493) $ (15,652) $ (4,928) $ (4,317) $ (21,577) ------------ ----------- ----------- ---------- ------------ CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS --------------------------------------------------------------------------------------- U.S. dollars in thousands Year ended Nine months ended Three months ended December September 30, September 30, 31, -------------------------- ------------------------- 2024 2023 2024 2023 2023 ----------- ------------- ------------ ----------- ----------- Unaudited ----------------------------------------------------- ----------- Cash flows from investing activities: ---------------- Purchase of property, plant and equipment $ (304) $ (699) $ (132) $ (216) $ (785) Proceeds from sale of marketable securities - 6,924 - - 6,924 Purchase of marketable securities - (503) - - (503) Proceeds from sale of property, plant and equipment 58 26 48 - 26 Investment in short term bank deposits, net 1,110 (9,700) 2,100 3,860 (10,200) Net cash provided by (used in) investing activities 864 (3,952) 2,016 3,644 (4,538) ----------- ------------- ------------ ----------- ----------- Cash flows from financing activities: ---------------- Issuance of a subsidiary preferred shares to non-controlling interests - 9,523 - - 9,523 Proceeds from issuance of ordinary shares, pre-funded warrants and warrants, net of issuance expenses 4,854 - 4,854 - - Proceeds from issuance of ordinary shares, net of issuance expenses 123 8,404 37 8,068 8,449 Repayment of lease liability (695) (624) (233) (211) (836) Proceeds from government grants 232 1,069 232 (20) 1,089 Repayment of government grants (298) (73) (156) (38) (73) Net cash provided by financing activities 4,216 18,299 4,734 7,799 18,152 ----------- ------------- ------------ ----------- ----------- Exchange rate differences - cash and cash equivalent balances (42) (344) 11 (28) (245) ----------- ------------- ------------ ----------- ----------- Increase (decrease) in cash and cash equivalents (9,455) (1,649) 1,833 7,098 (8,208) Cash and cash equivalents beginning of the period 20,772 28,980 9,484 20,233 28,980 ----------- ------------- ------------ ----------- ----------- Cash and cash equivalents end of the period $ 11,317 $ 27,331 $ 11,317 $ 27,331 $ 20,772 =========== ============= ============ =========== =========== Significant non-cash activities: ---------------- Acquisition of property, plant and equipment, net $ 28 $ 35 $ 28 $ 35 $ 81 =========== ============= ============ =========== =========== Increase of right-of-use asset recognized with corresponding lease liability $ 279 $ 135 $ 95 $ - $ 194 =========== ============= ============ =========== =========== Investment in $ 120 $ - $ - $ - $ - affiliated Company with corresponding deferred revenues =========== ============= ============ =========== ===========
  

• Press Release: Evogene Reports Third Quarter 2024 Financial Results, from 7:30AM ET on Thursday Nov 21, 2024 by Dow Jones

  7:30AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: EVGN